In recent clinical trials, ziltivekimab, a novel IL-6 ligand inhibitor, was highly effective in reducing inflammatory responses and biomarkers of atherosclerosis, suggesting that IL-6 is an effective therapeutic target for atherosclerosis (Ridker and Rane, 2021). This evidence concerns the gene IL6 and atherosclerosis.